3D Systems Corp. DDD
Our regular readers will recall our initial alert on DDD Options a week ago today– wherein we tagged the $52-53 Calls. In the sessions that followed, we were afforded the chance at some large gains.
The same ideas could have been put to work to kick off this week, so anyone who continued to track DDD along with us, is certainly sitting in a good position now.
For instance, the $52 Calls, which were trading at a low of 2.10, closed at 4.82, a 129% intraday move.
The $53 Calls fared even better, coming very close to yielding a double-bagger as they ran from a low of 1.37 up to 4.10, good for up to 199% in gains.
Some of the other stocks in the 3D Printing sector (Like VJET and SSYS) have also made big moves like DDD, while another play we’ve been monitoring in the space, ONVO, has yet to do so. For this reason, we want to put ONVO on watch as well, in the event that it follows suit with the other stocks in the industry.
IsoRay, Inc. ISR
ISR is one that we are going to add to our watchlist today, and it comes to us as a stock that we feel is in a good spot on its chart. We can see potential value here in the short, medium, or long term, and will begin tracking it from here on out.
As you can observe on the chart below, we’re looking at an ascending wedge on ISR, a pattern which can help to judge its trends. Whichever way it breaks out of the channel is generally where the trend will lead. A dip below support could mean heavy losses, while a breach of resistance could mean a serious breakout.
In premarket trading the stock is currently gapping up above that channel, so we have it on close watch to break out and possibly test its previous swing highs at 3.50 and above. A move past that area on the chart would mean a full-on Blue Sky Breakout, so we definitely want to pay attention.
BARCHART.COM is assigning ISR an 88% Overall “Buy” Rating
RICHLAND, WA–(Marketwired – Jun 24, 2014) – IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced another milestone — the treatment of a brain tumor that had metastasized from esophageal cancer utilizing IsoRay’s liquid Cesium-131 (Cesitrex®) which recently was FDA cleared for internal radiation therapy. >>> FULL PR
Extended Watchlist:
XGTI, LIVE, LIQD, CRMD, CDE
